WO2012068383A3 - ncRNA AND USES THEREOF - Google Patents

ncRNA AND USES THEREOF Download PDF

Info

Publication number
WO2012068383A3
WO2012068383A3 PCT/US2011/061204 US2011061204W WO2012068383A3 WO 2012068383 A3 WO2012068383 A3 WO 2012068383A3 US 2011061204 W US2011061204 W US 2011061204W WO 2012068383 A3 WO2012068383 A3 WO 2012068383A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
relates
present
ncrna
markers
Prior art date
Application number
PCT/US2011/061204
Other languages
French (fr)
Other versions
WO2012068383A2 (en
Inventor
Arul Chinnaiyan
John Prensner
Matthew Iyer
Original Assignee
The Regents Of The University Of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of Michigan filed Critical The Regents Of The University Of Michigan
Priority to AU2011329753A priority Critical patent/AU2011329753B2/en
Priority to EP11840840.0A priority patent/EP2640854B1/en
Priority to CN201180065510.1A priority patent/CN103403181B/en
Priority to CA2818486A priority patent/CA2818486C/en
Publication of WO2012068383A2 publication Critical patent/WO2012068383A2/en
Publication of WO2012068383A3 publication Critical patent/WO2012068383A3/en
Priority to AU2015242941A priority patent/AU2015242941B2/en
Priority to AU2017276340A priority patent/AU2017276340A1/en
Priority to AU2020201232A priority patent/AU2020201232A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Abstract

The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ncRNAs as diagnostic markers and clinical targets for prostate, lung, breast and pancreatic cancer.
PCT/US2011/061204 2010-11-19 2011-11-17 ncRNA AND USES THEREOF WO2012068383A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2011329753A AU2011329753B2 (en) 2010-11-19 2011-11-17 ncRNA and uses thereof
EP11840840.0A EP2640854B1 (en) 2010-11-19 2011-11-17 PCAT1 ncRNA AND USES THEREOF
CN201180065510.1A CN103403181B (en) 2010-11-19 2011-11-17 NcRNA and application thereof
CA2818486A CA2818486C (en) 2010-11-19 2011-11-17 Ncrna and uses thereof
AU2015242941A AU2015242941B2 (en) 2010-11-19 2015-10-12 ncRNA and uses thereof
AU2017276340A AU2017276340A1 (en) 2010-11-19 2017-12-15 ncRNA and uses thereof
AU2020201232A AU2020201232A1 (en) 2010-11-19 2020-02-20 ncRNA and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41549010P 2010-11-19 2010-11-19
US61/415,490 2010-11-19

Publications (2)

Publication Number Publication Date
WO2012068383A2 WO2012068383A2 (en) 2012-05-24
WO2012068383A3 true WO2012068383A3 (en) 2012-08-16

Family

ID=46084653

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/061204 WO2012068383A2 (en) 2010-11-19 2011-11-17 ncRNA AND USES THEREOF

Country Status (7)

Country Link
US (4) US20150284802A1 (en)
EP (2) EP2640854B1 (en)
CN (2) CN103403181B (en)
AU (4) AU2011329753B2 (en)
CA (2) CA3012765A1 (en)
HK (1) HK1256822A1 (en)
WO (1) WO2012068383A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
US20110136683A1 (en) 2008-05-28 2011-06-09 Genomedx Biosciences, Inc. Systems and Methods for Expression-Based Discrimination of Distinct Clinical Disease States in Prostate Cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
CA3012765A1 (en) 2010-11-19 2012-05-24 The Regents Of The University Of Michigan Ncrna and uses thereof
AU2012352153B2 (en) 2011-12-13 2018-07-26 Veracyte, Inc. Cancer diagnostics using non-coding transcripts
CA2881627A1 (en) 2012-08-16 2014-02-20 Genomedx Biosciences Inc. Cancer diagnostics using biomarkers
CN103146688B (en) * 2012-09-12 2015-05-13 上海长海医院 Application of long-chain non-coding RNA as blood molecular marker for disease diagnosis
WO2014152355A2 (en) * 2013-03-14 2014-09-25 The Broad Institute, Inc. Osteosarcoma-associated risk markers and uses thereof
WO2014205555A1 (en) * 2013-06-28 2014-12-31 British Columbia Cancer Agency Branch Methods and uses for diagnosis and treatment of prostate cancer
US10662480B2 (en) 2014-02-04 2020-05-26 Thomas Jefferson University Specific expression of half-tRNA in cancers
KR20170116009A (en) * 2014-12-01 2017-10-18 프라운호퍼-게젤샤프트 추어 푀르더룽 데어 안게반텐 포르슝 에.파우. Novel rna-biomarker signature for diagnosis of prostate cancer
CN106047875B (en) * 2015-06-04 2018-11-02 佛山市第一人民医院 LncRNA molecules and its application in nasopharyngeal carcinoma auxiliary diagnosis
CN105936904B (en) * 2015-06-04 2018-07-20 佛山市第一人民医院 LncRNA molecules ENST00000438553 and its application in nasopharyngeal carcinoma auxiliary diagnosis
CN106047876B (en) * 2015-06-04 2018-11-02 佛山市第一人民医院 A kind of nasopharyngeal carcinoma related molecule sign and its application
EP3390661B1 (en) * 2015-12-17 2022-05-04 Institut Curie Use of antisense long non-coding rnas for the diagnosis of prostate cancer
CN110023511A (en) * 2016-06-08 2019-07-16 Mir科學有限責任公司 For prostate cancer diagnosis and the method and composition for the treatment of
CN110506127B (en) 2016-08-24 2024-01-12 维拉科特Sd公司 Use of genomic tags to predict responsiveness of prostate cancer patients to post-operative radiation therapy
EP3571322B9 (en) 2017-01-20 2023-10-04 VERACYTE SD, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
US11873532B2 (en) 2017-03-09 2024-01-16 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
CA3062716A1 (en) 2017-05-12 2018-11-15 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
CN107729719B (en) * 2017-09-30 2020-05-26 中国科学院计算技术研究所 De novo sequencing method
JP2021502069A (en) * 2017-11-12 2021-01-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Non-coding RNA for detecting cancer
CN108998531B (en) * 2018-08-31 2021-10-01 昆明医科大学第一附属医院 Long-chain non-coding RNA marker for lung cancer down-regulation and application thereof
CN108998530B (en) * 2018-08-31 2021-10-08 昆明医科大学第一附属医院 Lung cancer up-regulated long-chain non-coding RNA marker and application thereof
WO2023152568A2 (en) * 2022-02-10 2023-08-17 Oslo Universitetssykehus Hf Compositions and methods for characterizing lung cancer
CN114480651B (en) * 2022-02-14 2023-10-20 天津市泌尿外科研究所 Antisense oligonucleotide of PCAT1 and application thereof in preparation of medicaments for inhibiting prostate cancer nucleic acid

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080076674A1 (en) * 2006-07-06 2008-03-27 Thomas Litman Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323546A (en) 1978-05-22 1982-04-06 Nuc Med Inc. Method and composition for cancer detection in humans
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
EP0232967B1 (en) 1986-01-10 1993-04-28 Amoco Corporation Competitive homogeneous assay
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5283174A (en) 1987-09-21 1994-02-01 Gen-Probe, Incorporated Homogenous protection assay
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5225326A (en) 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
KR100242252B1 (en) 1989-07-11 2000-03-02 다니엘 엘. 캐시앙 Nucleic acid sequence amplification methods
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
US5270184A (en) 1991-11-19 1993-12-14 Becton, Dickinson And Company Nucleic acid target generation
US5545524A (en) 1991-12-04 1996-08-13 The Regents Of The University Of Michigan Compositions and methods for chromosome region-specific probes
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
JP3189000B2 (en) 1994-12-01 2001-07-16 東ソー株式会社 Specific nucleic acid sequence detection method
US5710029A (en) 1995-06-07 1998-01-20 Gen-Probe Incorporated Methods for determining pre-amplification levels of a nucleic acid target sequence from post-amplification levels of product
US5854206A (en) 1995-08-25 1998-12-29 Corixa Corporation Compounds and methods for treatment and diagnosis of prostate cancer
US6121489A (en) 1996-03-05 2000-09-19 Trega Biosciences, Inc. Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein
AR006250A1 (en) 1996-03-15 1999-08-11 Corixa Corp COMPOUNDS AND METHODS FOR IMMUNOTHERAPY AND IMMUNODIAGNOSIS OF PROSTATIC CANCER
CA2252048C (en) 1996-04-12 2008-03-11 The Public Health Research Institute Of The City Of New York, Inc. Detection probes, kits and assays
HUP0002095A3 (en) 1997-02-25 2002-02-28 Corixa Corp Seattle Compounds for immunotherapy of prostate cancer and methods for their use
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
AU6449398A (en) 1997-03-07 1998-09-22 Clare Chemical Research Llc Fluorometric detection using visible light
ES2402947T3 (en) 1997-04-10 2013-05-10 Stichting Katholieke Universiteit University Medical Centre Nijmegen PCA3, PCA3 genes and methods of use
US20030044783A1 (en) * 2000-03-09 2003-03-06 Williams Lewis T. Human genes and gene expression products
EP1092047B1 (en) 1998-07-02 2009-08-26 Gen-Probe Incorporated Molecular torches
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
US6828429B1 (en) 1999-03-26 2004-12-07 Henry M. Jackson Foundation For The Advancement Of Military Medicine Prostate-specific gene, PCGEM1, and the methods of using PCGEM1 to detect, treat, and prevent prostate cancer
US6303305B1 (en) 1999-03-30 2001-10-16 Roche Diagnostics, Gmbh Method for quantification of an analyte
DE60014762T2 (en) 1999-05-24 2005-10-13 Tosoh Corp., Shinnanyo Method for the detection of ribonucleic acids
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
ATE309393T1 (en) 2001-09-06 2005-11-15 Adnagen Ag METHOD FOR THE QUALITATIVE AND/OR QUANTITATIVE DETECTION OF CELLS
DE60235413D1 (en) * 2001-12-07 2010-04-01 Novartis Vaccines & Diagnostic IN PROSTATE CANCER HIGHLY REGULATED ENDOGENIC RETROVIRUS
US8679789B2 (en) 2003-05-01 2014-03-25 Gen-Probe Incorporated Oligonucleotides comprising a molecular switch
US20050118625A1 (en) * 2003-10-02 2005-06-02 Mounts William M. Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases
EP2071031B1 (en) 2004-08-27 2013-10-09 Gen-Probe Incorporated Single-primer nucleic acid amplification methods
US9957569B2 (en) * 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US20070172841A1 (en) * 2006-01-25 2007-07-26 Hui Wang Probe/target stabilization with add-in oligo
US20110045464A1 (en) * 2007-01-10 2011-02-24 Henry Ford Health System Methods and compositions for identification of prostate cancer markers
EP2173908B1 (en) 2007-08-03 2016-01-06 The Ohio State University Research Foundation Ultraconserved regions encoding ncrnas
CA3012765A1 (en) 2010-11-19 2012-05-24 The Regents Of The University Of Michigan Ncrna and uses thereof
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080076674A1 (en) * 2006-07-06 2008-03-27 Thomas Litman Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BUSSEMAKERS, M. J. ET AL.: "DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.", CANCER RESEARCH., vol. 59, no. 23, 1 December 1999 (1999-12-01), pages 5975 - 5979, XP002923011 *
FU, X. ET AL.: "Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene", PCGEM1. DNA AND CELL BIOLOGY., vol. 25, no. 3, March 2006 (2006-03-01), pages 135 - 141, XP055107442 *
PRENSNER, J. R. ET AL.: "Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression.", NATURE BIOTECHNOLOGY, vol. 29, no. 8, 31 July 2011 (2011-07-31), pages 742 - 749, XP055106101 *
TAFT, R. J. ET AL.: "Non-coding RNAs: regulators of disease.", THE JOURNAL OF PATHOLOGY., vol. 220, no. 2, January 2010 (2010-01-01), pages 126 - 139, XP055107448 *

Also Published As

Publication number Publication date
CN106434870A (en) 2017-02-22
AU2020201232A1 (en) 2020-03-12
AU2011329753B2 (en) 2015-07-23
US20160251729A1 (en) 2016-09-01
CN103403181A (en) 2013-11-20
US20150284802A1 (en) 2015-10-08
HK1256822A1 (en) 2019-10-04
US20200165682A1 (en) 2020-05-28
AU2017276340A1 (en) 2018-01-18
CA3012765A1 (en) 2012-05-24
EP2640854A4 (en) 2014-05-07
CA2818486C (en) 2018-09-11
AU2011329753A1 (en) 2013-06-06
US20230016456A1 (en) 2023-01-19
AU2015242941A1 (en) 2015-10-29
AU2015242941B2 (en) 2017-12-21
WO2012068383A2 (en) 2012-05-24
EP2640854B1 (en) 2018-02-21
EP2640854A2 (en) 2013-09-25
EP3336200A1 (en) 2018-06-20
US11390923B2 (en) 2022-07-19
CN103403181B (en) 2016-09-07
CA2818486A1 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
WO2012068383A3 (en) ncRNA AND USES THEREOF
WO2012174256A3 (en) Dna methylation profiles in cancer
WO2010081001A3 (en) Recurrent gene fusions in cancer
WO2013089882A3 (en) Recurrent gene fusions in breast cancer
WO2011034906A3 (en) Recurrent gene fusions in prostate cancer
WO2012158780A3 (en) Lung cancer signature
WO2009111643A3 (en) Microrna markers for recurrence of colorectal cancer
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2010099161A8 (en) Micrornas in never-smokers and related materials and methods
MX2013002084A (en) Biomarkers and methods of treatment.
WO2012170776A3 (en) Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
WO2011103016A3 (en) Compositions and methods for inhibiting ezh2
WO2008089397A3 (en) Adrb2 cancer markers
WO2011008696A3 (en) Diagnostic methods and compositions for treatment of cancer
EP3683320A3 (en) Mirna fingerprint in the diagnosis of lung cancer
WO2011037643A3 (en) Compositions and methods for detecting and treating prostate carcinoma
MX2019000225A (en) Compositions and methods for treatment of autoimmune and other disease.
WO2013025952A3 (en) Methods and compositions for the treatment and diagnosis of breast cancer
WO2012083969A3 (en) Microrna for diagnosis of pancreatic cancer
WO2012012750A8 (en) Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
WO2011002834A3 (en) Compositions and methods for diagnosis and treatment of type 1 diabetes
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
CA2835730C (en) Molecular markers in prostate cancer
WO2009103741A3 (en) Use of fsh receptor ligands for diagnosis and therapy of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11840840

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2818486

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2011329753

Country of ref document: AU

Date of ref document: 20111117

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011840840

Country of ref document: EP